ClinicalTrials.gg
Active, not recruitingNCT06297603Updated Nov 17, 2026

Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

A Phase 3 interventional study of Retatrutide and Placebo in Type 2 Diabetes, sponsored by Eli Lilly and Company. Active, not recruiting at 76 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Updated Nov 17, 2026Enrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
341
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing retatrutide in Diabetes Mellitus, Type 2 — none open to participants now, 3 under way, 3 of them phase 3. retatrutide · Diabetes Mellitus, Type 2.

Enrollment
5th of 10
341 · median 311
Started
2024
with 3 others
Phase 3
5 of 10
none open now
Registered
7th of 10
by date
Lead sponsor
10 of 10
Eli Lilly and Company

Among the 10 studies testing retatrutide in Diabetes Mellitus, Type 2, this one is the 5th largest by enrollment, is one of 4 that started in 2024, is one of 5 in phase 3, and was the 7th registered.

Diabetes Mellitus, Type 2

10,392 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 10 studies testing retatrutide in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About retatrutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing retatrutide in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate glycemic control on basal insulin alone or a combination of basal insulin with or without metformin and/or sodium-glucose cotransporter-2 (SGLT2) inhibitor. The study will last about 14 months and may include up to 22 visits.

03

Conditions studied

  • Type 2 Diabetes

Keywords

  • Glucose Metabolism Disorders
  • Metabolic Diseases
  • Endocrine System Diseases
  • Diabetes Mellitus
  • Diabetes Mellitus, Type 2
  • Kidney Disease
  • Renal Insufficiency Chronic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have Type 2 Diabetes (T2D)
  • Have ≥7.0% (53 millimoles per mole (mmol/mol)) to ≤10.5% (91 mmol/mol)
  • Have moderate or severe renal impairment
  • Have been on the following stable diabetes treatment during 90 days prior to screening

    • basal insulin (≥20 International Units (IU)/day) with or without
    • metformin and/or SGLT2 inhibitor
  • Are of stable weight for at least 90 days prior to screening
  • Have a (BMI) ≥23.0 kilograms per meter squared (kg/m2)

Exclusion criteria

Exclusion Criteria:

  • Have Type 1 Diabetes (T1D)
  • Have a history of ketoacidosis or hyperosmolar state or coma within the last 6 months prior to screening
  • Have a history of severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to screening
  • Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema
  • Have a history of unstable or rapidly progressing renal disease
  • Have a prior or planned surgical treatment for obesity
  • Have Functional Classification III or IV congestive heart failure
  • Have had acute myocardial infarction, stroke, or were hospitalized for congestive heart failure within 90 days prior to screening
  • Have a known gastric emptying abnormality
  • Have a history of an active or untreated or are in remission from a clinically significant malignancy for less than 5 years
  • Have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) syndrome Type 2.
  • Have any lifetime history of a suicide attempt
  • Had chronic or acute pancreatitis
  • Have taken prescribed or over-the-counter medication, or alternative remedies, intended to promote body weight reduction within 90 days prior to screening
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
341 participants (actual)

Study arms

  • Experimental
    Retatrutide Dose 1

    Participants will receive retatrutide administered subcutaneously (SC).

    Drug: Retatrutide

  • Experimental
    Retatrutide Dose 2

    Participants will receive retatrutide administered SC.

    Drug: Retatrutide

  • Experimental
    Retatrutide Dose 3

    Participants will receive retatrutide administered SC.

    Drug: Retatrutide

  • Placebo comparator
    Placebo

    Participants will receive placebo administered SC.

    Drug: Placebo

Interventions

  • Administered SC

    Also known as: LY3437943

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Hemoglobin A1c (HbA1c) (%)

    Time frame: Baseline, Week 52

Secondary outcomes

  1. Percentage of Participants Achieving HbA1c <7.0%

    Time frame: Week 52

  2. Percentage of Participants Achieving HbA1c ≤6.5%

    Time frame: Week 52

  3. Change from Baseline in Fasting Serum Glucose

    Time frame: Baseline, Week 52

  4. Percentage of Time Continuous Glucose Monitoring (CGM) Glucose Values are Between 70 and 180 mg/dL

    Measured during the CGM session that occurs during 30 days prior to Week 52

    Time frame: Week 52

  5. Percent Change from Baseline in Body Weight

    Time frame: Baseline, Week 52

  6. Change from Baseline in Body Weight

    Time frame: Baseline, Week 52

  7. Percentage of Participants Achieving Weight Reduction of ≥5%

    Time frame: Week 52

  8. Percentage of Participants Achieving Weight Reduction of ≥10%

    Time frame: Week 52

  9. Percentage of Participants Achieving Weight Reduction of ≥15%

    Time frame: Week 52

  10. Percentage of Participants Achieving HbA1c ≤6.5% and ≥10% Weight Reduction

    Time frame: Week 52

  11. Percent Change from Baseline in Non-HDL Cholesterol

    Time frame: Baseline, Week 52

  12. Percent Change from Baseline in Triglycerides

    Time frame: Baseline, Week 52

  13. Change from Baseline in Systolic Blood Pressure (SBP)

    Time frame: Baseline, Week 52

07

Study locations

76 sites
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Oct 2026, 31 months.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 31 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2024
First posted
Mar 7, 2024
StartActual
Mar 15, 2024
Primary completionActual
Oct 26, 2026
CompletionEst.
Nov 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
320 (estimated)→341 (actual)
Nov 17, 2026
Show all 2 updates
  1. Nov 17, 2026
    Enrollment 320 (estimated)→341 (actual)
  2. Nov 13, 2026
    Minor edits only
    + 3 other changes: verification date, date precision and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06297603
Responsible party
Sponsor
First posted
Mar 7, 2024
Start date
Mar 15, 2024
Primary completion
Oct 26, 2026
Completion
Nov 2026 (estimated)
Last update
Nov 17, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Retatrutide

Start the discussion